NCT05382299: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician’s Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients who have previously received topoisomerase 1 inhibitors, including antibody drug conjugates (e.g. Irinotecan hydrochloride, Etirinotecan pegol, datopotamab deruxtecan/Dato-DXd/DS-1062a, Enhertu/Trastuzumab deruxtecan)

Comments are closed.

Up ↑